COVID-19 New Drug Concerns, Research Breakthroughs And Updated Mortality Statistics

A brief look at glucocorticoids, the Lancets updated mortality statistics, Hydroxychloroquine risks, lung treatments, viral treatment, and stem cell treatments

The Lancet Infectious Diseases: Comprehensive COVID-19 hospitalisation and death rate estimates help countries best prepare as global pandemic unfolds

https://www.eurekalert.org/pub_releases/2020-03/tl-pss_1033020.php#.XoKIMrdEpR0.wordpress

Mayo Clinic outlines approach for patients at risk of drug-induced sudden cardiac death in COVID-19

https://ekaprdweb01.eurekalert.org/pub_releases/2020-03/mc-mco032520.php

Individuals taking class of steroid medications at high risk for COVID-19

https://www.eurekalert.org/pub_releases/2020-03/tes-itc033120.php

Perhaps we will not need all the ventilators after all

https://www.eurekalert.org/pub_releases/2020-03/au-pww032620.php

HSC professor on team using stem cells to combat COVID-19 pneumonia

https://www.eurekalert.org/pub_releases/2020-03/uont-hpo032920.php

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

https://www.eurekalert.org/pub_releases/2020-03/tiom-nie032420.php

Researchers investigate potential treatments for COVID-19

https://ekaprdweb01.eurekalert.org/pub_releases/2020-03/asfm-rip032620.php

COVID-19: Stopgap measure to treat respiratory distress

https://www.eurekalert.org/pub_releases/2020-03/miot-asm032520.php

Categories: Misc....

Tags: ant-malaria, asthma medication, Covid-19, covid19, ecg, fusan, glucocorticoids, Hydroxychloroquine, lung clot treatments, Nafamostat, plasminogen, qt, remdesivir, SARS-CoV-2, Senicapoc, stem cells, tilarone, Tissue plasminogen activator